Filing Flows › Health Care › Zevra Therapeutics (ZVRA)
Zevra Therapeutics (ZVRA) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 3, 2026 · Zevra Therapeutics (ZVRA) Q3 2026 earnings results →
Q3 2026 Revenue up 45% year over year to $37.8M · 51¢ of every $1 of revenue kept as net profit · operating margin 30.7%
Zevra Therapeutics made $37.8M in Q3 2026 (+45% Y/Y). Operating margin 30.7%, net earnings $19.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 3, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $37.8M in Q3 2026, up 45% year over year and down 5% from the previous quarter.
Operating profit was $11.6M, a 30.7% margin (up 14.8 points year over year). Of the extra revenue versus Q3 2025, 64% reached operating profit, above the 16% margin then. Total costs grew 19% against revenue growth of 45%. The fastest-growing cost line was Cost of revenue (+45%). Net earnings were $19.2M. The effective tax rate was 2.6%. Non-operating items added $8.1M, 41% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $10.0M (up 113% year over year), 52% of net earnings. Non-cash charges added back $378K of depreciation and amortization and $2.7M of share-based compensation. Working capital and other items used $12.2M. Capital expenditures of $238K left free cash flow of $9.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 3, 2026 | $37.8M | +45% | 30.7% | $19.2M | $10.0M |
| Q2 2026 | 10-Q | Aug 5, 2026 | $39.7M | +53% | 42.3% | $8.8M | $17.0M |
| Q1 2026 | 10-Q | May 6, 2026 | $36.2M | +78% | 144.0% | $37.9M | $6.1M |
| Q4 2025 | 10-K | Mar 9, 2026 | $34.1M | +183% | 27.3% | $12.2M | $5.5M |
| Q3 2025 | 10-Q | Nov 5, 2025 | $26.1M | +605% | 15.9% | −$544K | $4.7M |
| Q2 2025 | 10-Q | Aug 12, 2025 | $25.9M | +482% | -274.5% | $74.7M | −$3.6M |
| Q1 2025 | 10-Q | May 13, 2025 | $20.4M | +496% | -26.3% | −$3.1M | −$8.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Zevra Therapeutics
We are a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. We are focused on expanding patient access, progressing our pipeline toward key milestones, and delivering meaningful therapeutics. Our vision is realized through disciplined execution of our strategic plan and our core values — patient centricity, integrity, accountability, innovation, and courage — which guide our efforts to deliver long-term value. The commercialization of our lead product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and demonstrates our ability to advance therapies from development to market.
In its own words, from its 10-K, filed Mar 9, 2026.
Zevra Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +45% against the peers' median +10%. Operating margin: 30.7% against the peers' median 30.7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ZVRA Zevra Therapeutics | Q3 2026 | $37.8M | +45% | 30.7% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Zevra Therapeutics 10-Q on SEC EDGAR · CIK 1434647 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns ZVRA and who is buying
More on ZVRA
- How Zevra Therapeutics makes money: revenue by segment
- Zevra Therapeutics next earnings date and what analysts expect
- Zevra Therapeutics stock forecast, price target and fair value
- Who owns Zevra Therapeutics stock: holders, funds and Congress trades
- Zevra Therapeutics guidance and outlook
- Is Zevra Therapeutics a takeover target? LBO and rumors
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results